Abstract: The present invention relates to a hemostatic composition and a method for preparing thereof, and more specifically, relates to a hemostatic composition comprising a cross-linked hyaluronic acid derivative matrix which is suitable to be used for hemostasis and a method of preparation of such a composition.

Abstract: The present invention relates to a composition for treating osteoarthritis and a method for preparing the same, and more specifically, relates to a composition comprising hydrophilized sulfasalazine as an active ingredient and hyaluronic acid so as to enable effective treatment of osteoarthritis such as degenerative osteoarthritis by preventing joint wear in addition to symptom relief through intraarticular or local administration, and a method for preparing the same.

Abstract: The present invention relates to a composition for treating osteoarthritis and a method for preparing the same, and more specifically, relates to a composition comprising hydrophilized sulfasalazine as an active ingredient and hyaluronic acid so as to enable effective treatment of osteoarthritis such as degenerative osteoarthritis by preventing joint wear in addition to symptom relief through intraarticular or local administration, and a method for preparing the same.

Abstract: The present invention refers to the injectable hyaluronic acid composition which is crosslinked viscoelastic hyaluronic acid gel comprising DNA fractions. More particularly, it refers to the injectable hyaluronic acid composition comprising a hyaluronic acid composition crosslinked in the basic conditions with the degree of crosslinking between 0.1 and 200%, which is mixed with the DNA fractions of 0.1 to 50 wt %. The DNA fractions are selected, for example, from polynucleotide (PN) and polydeoxyribonucleotide (PDRN). The composition used for cosmetic purposes or therapeutic purposes, have improved viscoelastic rheological properties and enzyme resistance.

Abstract: The present invention relates to a hemostatic composition and a method for preparing thereof, and more specifically, relates to a hemostatic composition comprising a cross-linked hyaluronic acid derivative matrix which is suitable to be used for hemostasis and a method of preparation of such a composition.

Abstract: The present invention relates to a composition for treating osteoarthritis and a method for preparing the same, and more specifically, relates to a composition comprising hydrophilized sulfasalazine as an active ingredient and hyaluronic acid so as to enable effective treatment of osteoarthritis such as degenerative osteoarthritis by preventing joint wear in addition to symptom relief through intraarticular or local administration, and a method for preparing the same.

Abstract: The present invention refers to the injectable hyaluronic acid composition which is crosslinked viscoelastic hyaluronic acid gel comprising DNA fractions. More particularly, it refers to the injectable hyaluronic acid composition comprising a hyaluronic acid composition crosslinked in the basic conditions with the degree of crosslinking between 0.1 and 200%, which is mixed with the DNA fractions of 0.1 to 50 wt %. The DNA fractions are selected, for example, from polynucleotide (PN) and polydeoxyribonucleotide (PDRN). The composition used for cosmetic purposes or therapeutic purposes, have improved viscoelastic rheological properties and enzyme resistance.

Abstract: This invention relates to a stable liquid formulation comprising hyaluronidase and a stabilizer for hyaluronidase and more particularly, to a stable liquid formulation by the addition of the stabilizer to the hyaluronidase.

Abstract: This invention relates to a stable hyaluronidase liquid formulation comprising a hyaluronidase and a stabilizer for hyaluronidase. In particular, the hyaluronidase has a purity of 95% or more and the specific activity of 70,000 IU/mg or more, and the stabilizer for hyaluronidase contains a buffering agent in order to provide pH of 4.0 to 6.0; 0.001 to 0.5 v/v % of a non-ionic surfactant; and 0.1 to 5 mM of a chelating agent or MgCl2. The liquid formulation has advantages in that it stably maintains its activity for a long period of time and may be easily administered than the conventional formulations.

Abstract: The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

Abstract: This invention relates to a stable liquid formulation comprising hyaluronidase and a stabilizer for hyaluronidase and more particularly, to a stable liquid formulation by the addition of the stabilizer to the hyaluronidase.

Abstract: The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.